Revolution Medicines Reports Promising Clinical Data for Zoldonrasib in KRAS G12D Mutant Non-Small Cell Lung Cancer at AACR Annual Meeting
27/4 18:10
Revolution Medicines announced promising clinical data for zoldonrasib, a treatment for KRAS G12D mutant non-small cell lung cancer....